Journey Medical Corporation (DERM)

Market Cap	164.93M +3.7%
Revenue (ttm)	64.68M +15.0%
Net Income	-9.59M
EPS	-0.37
Shares Out	27.53M
PE Ratio	n/a
Forward PE	40.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	139,965
Open	6.16
Previous Close	6.12
Day's Range	5.96 - 6.18
52-Week Range	4.31 - 9.56
Beta	1.04
Analysts	Strong Buy
Price Target	13.50 (+125.38%)
Earnings Date	May 13, 2026

About DERM

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to se...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 12, 2021
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: DERM
• Website: https://journeymedicalcorp.com

Financial Performance

In 2025, Journey Medical's revenue was $61.86 million, an increase of 10.20% compared to the previous year's $56.13 million. Losses were -$11.43 million, -22.09% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 125.38% from the latest price.

Price Target

$13.5

(125.38% upside)

Analyst Consensus: Strong Buy